TomoTherapy Announces First Middle East Installation of Hi·Art® Cancer Treatment System

Saudi Arabia’s renowned King Faisal Specialist Hospital & Research Centre will become region’s first to treat cancer patients with next-generation radiation therapy solution

MADISON, Wis. – March 24, 2009 – TomoTherapy Incorporated (NASDAQ: TOMO) announced today that Saudi Arabia’s leading cancer center, King Faisal Specialist Hospital & Research Centre (KFSH&RC) in Riyadh, will become the region’s first to treat patients with the Hi·Art^® treatment system, a next-generation radiation therapy solution designed to improve the precision of cancer care. KFSH&RC commemorated the historic Hi·Art treatment system installation in a ribbon-cutting ceremony during a scientific meeting held at the hospital March 9-12, 2009.

The meeting, entitled “Innovative Approaches in Radiotherapy: Beyond Tomorrow”, attracted radiation oncology professionals from throughout the country and featured an impressive roster of speakers, including TomoTherapy co-founder and Chairman of the Board Thomas “Rock” Mackie, Ph.D.

“It was an honor for me to attend both the scientific meeting and Hi·Art system opening ceremony hosted by King Faisal Specialist Hospital & Research Centre,” said Dr. Mackie. “TomoTherapy is extremely pleased to partner with this world-renowned centre as it implements the only solution designed to deliver on the promises of image-guided, intensity-modulated radiation therapy (IG-IMRT).”

TomoTherapy’s Hi·Art treatment system is unique among radiation therapy devices in its computed tomography (CT) scanner-based design. The system allows clinicians to efficiently acquire a true CT image of the patient immediately before daily treatment to help ensure accuracy. Then, using the same equipment as used in imaging, the treatment team can deliver highly-precise radiation in a continuous, 360-degree (helical) pattern.

“We look forward to employing TomoTherapy^® treatment technology to benefit our patients in terms of minimization of dose to normal tissue and improvement of side-effect related outcomes,” said Dr. Mohammad Al-Shabanah, Section Head, Radiation Oncology, KFSH&RC. “One area of interest for us is the use of total marrow irradiation to support our large bone marrow transplant program.”

Added Dr. Belal Moftah, Chairman, Department of Biomedical Physics, KFSH&RC: “We are very excited at King Faisal Specialist Hospital & Research Centre to open our TomoTherapy unit, which is the first in the Middle East. We plan on maximizing the advantages of integrated CT imaging and highly-modulated beam delivery that TomoTherapy provides. Additionally, we are extremely satisfied with the speed of installation and professionalism of both TomoTherapy and its distribution partner in Saudi Arabia, AttiehMedico.com.”

About TomoTherapy Incorporated

TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy^® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy’s suite of solutions include its flagship Hi·Art^® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD^™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile^™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

24 Mar 2009

• Recent Treatment Center News
• Treatment Center News Archives